Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin[1][2][3].
Molecular Weight:
608.91
Purity:
99.20
CAS Number:
[2733573-94-7]
Formula:
C29H14ClF5N6O2
Target:
PI3K
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
